Second‐line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild‐type KRAS

The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second‐line chemotherapy in patients with irinotecan‐refractory and oxaliplatin‐naïve metastatic colorectal cancer (mCRC) harboring wild...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Sci
Glavni autori: Hong, Yong Sang, Kim, Hwa Jung, Park, Seong Joon, Kim, Kyu‐Pyo, Lee, Jae‐Lyun, Park, Jin Hong, Kim, Jong Hoon, Lim, Seok‐Byung, Yu, Chang Sik, Kim, Jin Cheon, Baek, Ji Yeon, Kim, Sun Young, Kim, Tae Won
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2013
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657158/
https://ncbi.nlm.nih.gov/pubmed/23298313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12098
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items